Cyclacel Pharmaceuticals (CYCC) Competitors $0.32 -0.01 (-4.11%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CYCC vs. BCLI, ENSC, BFRI, AYTU, ADXN, VIRX, CDT, OBSV, CERO, and SNGXShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Brainstorm Cell Therapeutics (BCLI), Ensysce Biosciences (ENSC), Biofrontera (BFRI), Aytu BioPharma (AYTU), Addex Therapeutics (ADXN), Viracta Therapeutics (VIRX), Conduit Pharmaceuticals (CDT), ObsEva (OBSV), CERo Therapeutics (CERO), and Soligenix (SNGX). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Brainstorm Cell Therapeutics Ensysce Biosciences Biofrontera Aytu BioPharma Addex Therapeutics Viracta Therapeutics Conduit Pharmaceuticals ObsEva CERo Therapeutics Soligenix Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking. Is CYCC or BCLI more profitable? Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -18,150.00%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals-18,150.00% -1,901.11% -188.23% Brainstorm Cell Therapeutics N/A N/A -528.56% Which has better earnings & valuation, CYCC or BCLI? Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Cyclacel Pharmaceuticals. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclacel Pharmaceuticals$74K26.97-$22.56M-$9.40-0.03Brainstorm Cell TherapeuticsN/AN/A-$17.19M-$4.80-0.48 Do institutionals and insiders hold more shares of CYCC or BCLI? 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 8.0% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, CYCC or BCLI? Cyclacel Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Does the media favor CYCC or BCLI? In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for Brainstorm Cell Therapeutics. Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score. Company Overall Sentiment Cyclacel Pharmaceuticals Neutral Brainstorm Cell Therapeutics Neutral Do analysts rate CYCC or BCLI? Cyclacel Pharmaceuticals currently has a consensus price target of $11.00, indicating a potential upside of 3,365.66%. Brainstorm Cell Therapeutics has a consensus price target of $30.00, indicating a potential upside of 1,215.79%. Given Cyclacel Pharmaceuticals' higher possible upside, equities analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Brainstorm Cell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CYCC or BCLI? Brainstorm Cell Therapeutics received 104 more outperform votes than Cyclacel Pharmaceuticals when rated by MarketBeat users. Likewise, 61.26% of users gave Brainstorm Cell Therapeutics an outperform vote while only 46.87% of users gave Cyclacel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCyclacel PharmaceuticalsOutperform Votes18746.87% Underperform Votes21253.13% Brainstorm Cell TherapeuticsOutperform Votes29161.26% Underperform Votes18438.74% SummaryCyclacel Pharmaceuticals beats Brainstorm Cell Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.00M$6.57B$5.13B$9.08BDividend YieldN/A2.99%4.93%4.22%P/E Ratio-0.0310.5589.5817.18Price / Sales26.97195.351,115.01116.87Price / CashN/A57.1642.8237.86Price / Book0.565.104.804.78Net Income-$22.56M$151.51M$120.04M$225.60M7 Day Performance-12.10%-2.12%-1.91%-1.23%1 Month Performance-8.61%-3.10%11.48%3.36%1 Year Performance-91.18%11.54%30.59%16.59% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals2.304 of 5 stars$0.32-4.1%$11.00+3,365.7%-91.2%$2.00M$74,000.00-0.0314Analyst ForecastGap UpBCLIBrainstorm Cell Therapeutics3.9873 of 5 stars$1.54+6.0%$30.00+1,852.7%-21.2%$8.76MN/A-0.3040Gap UpENSCEnsysce Biosciences0.085 of 5 stars$6.62+17.8%N/A-49.1%$8.65M$2.23M-0.2010BFRIBiofrontera1.4519 of 5 stars$1.11+4.7%$7.00+530.6%-69.7%$8.60M$35.36M-0.4770Gap DownAYTUAytu BioPharma0.8898 of 5 stars$1.39-3.5%N/A-52.9%$8.55M$81M-1.17160Positive NewsADXNAddex Therapeutics2.7065 of 5 stars$8.02+0.3%$30.00+274.1%+39.1%$8.50M$556,045.00-23.5330Gap DownVIRXViracta Therapeutics2.5296 of 5 stars$0.20+0.6%$5.00+2,351.0%-56.7%$8.11MN/A-0.1820Gap DownCDTConduit PharmaceuticalsN/A$0.08-4.8%N/A-98.5%$7.98MN/A0.003OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageCEROCERo TherapeuticsN/A$0.05-8.1%N/AN/A$7.83MN/A0.008SNGXSoligenix0.7346 of 5 stars$3.06-3.2%N/A-69.6%$7.68M$840,000.00-0.4220Positive NewsGap Up Related Companies and Tools Related Companies Brainstorm Cell Therapeutics Competitors Ensysce Biosciences Competitors Biofrontera Competitors Aytu BioPharma Competitors Addex Therapeutics Competitors Viracta Therapeutics Competitors Conduit Pharmaceuticals Competitors ObsEva Competitors CERo Therapeutics Competitors Soligenix Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYCC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts